← IDEAYA Biosciences, Inc.
| Annual Trend | FY 2011 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income From Continuing Operations | — | — | ($34.3m) | ($42.0m) | ($34.5m) | ($49.8m) | ($58.7m) | ($113.0m) | ($274.5m) | ($113.7m) | ($175.0m) | |
| Net loss | ($3.1m) | ($11.9m) | ($34.3m) | ($42.0m) | ($34.5m) | ($49.8m) | ($58.7m) | ($113.0m) | ($274.5m) | ($113.7m) | — | |
| Depreciation, Depletion and Amortization | $400k | $391k | $886k | $1.2m | $1.4m | $1.7m | $2.1m | $2.5m | $2.4m | $2.7m | $4.5m | |
| Net amortization (accretion) of premiums (discounts) on marketable securities | — | ($27k) | ($808k) | ($473k) | $578k | $1.8m | ($695k) | ($11.6m) | ($23.2m) | ($10.0m) | — | |
| Amortization of right of use assets | — | — | — | — | — | $1.3m | $1.4m | $1.5m | $1.4m | $1.9m | — | |
| Amortization Of Securities | — | — | — | — | — | — | ($695k) | ($11.6m) | ($23.2m) | ($10.0m) | ($5.7m) | |
| Depreciation Amortization Depletion | — | — | — | — | — | — | $3.5m | $4.0m | $3.8m | $4.6m | $4.5m | |
| Share-based Payment Arrangement, Noncash Expense | — | — | $950k | $2.2m | $3.6m | $8.2m | $11.6m | $18.5m | $34.7m | $46.1m | $55.2m | |
| Share-based Payment Arrangement, Expense | — | — | $950k | $2.2m | $3.6m | $8.2m | $11.6m | $18.5m | $34.7m | $46.1m | $55.2m | |
| Stock-based compensation | $2.5m | $136k | $950k | $2.2m | $3.6m | $8.2m | $11.6m | $18.5m | $34.7m | $46.1m | $55.2m | |
| Other Nonoperating Income (Expense) | — | — | $77k | $8k | — | — | — | — | — | — | — | |
| Nonoperating Income (Expense) | — | — | — | — | $849k | $506k | $3.8m | $21.5m | $52.5m | $45.6m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Change In Working Capital | — | — | — | — | — | — | ($43.0m) | ($13.2m) | $11.5m | $1.9m | $9.4m | |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | $1.9m | ($774k) | ($892k) | ($193k) | ($15k) | $0 | $0 | |
| Accounts receivable | ($170k) | — | — | $0 | ($1.9m) | $774k | $892k | $193k | $15k | $0 | $0 | |
| Change In Receivables | — | — | — | — | — | — | $892k | $193k | $0 | $0 | $0 | |
| Changes In Account Receivables | — | — | — | — | — | — | $892k | $193k | $0 | $0 | $0 | |
| Inventories | $173k | — | — | — | — | — | — | — | — | — | — | |
| Increase (Decrease) in Accounts Payable | $153k | $254k | $322k | ($195k) | $225k | $1.2m | $1.9m | $2.6m | $8.3m | $2.7m | $12.3m | |
| Purchases of property and equipment in accounts payable and accrued liabilities | — | $70k | $604k | $0 | $520k | $92k | $384k | $147k | $1.5m | $1.1m | ($2.2m) | |
| Change In Payables And Accrued Expense | — | — | — | — | — | — | $6.4m | $4.3m | $19.1m | $13.1m | $12.3m | |
| Accrued and other liabilities | — | $1.0m | $1.7m | $2.0m | $3.0m | $4.2m | $4.6m | $1.6m | $10.8m | $10.4m | — | |
| Change In Accrued Expense | — | — | — | — | — | — | $4.6m | $1.6m | $10.8m | $10.4m | $13.2m | |
| Prepaid expenses and other assets | — | $331k | ($243k) | ($2.0m) | ($510k) | ($189k) | ($2.1m) | ($2.0m) | ($6.2m) | ($7.8m) | — | |
| Change In Other Current Assets | — | — | — | — | — | $1.3m | $1.4m | — | — | — | $1.4m | |
| Change In Other Current Liabilities | — | — | — | — | — | — | ($1.7m) | ($1.9m) | ($1.4m) | $2.6m | $2.7m | |
| Net Cash Provided by (Used in) Operating Activities | $2.6m |
($12.2m)
-572.90%
|
($27.6m)
-125.95%
|
($39.3m)
-42.34%
|
$55.5m
+241.08%
|
($55.8m)
-200.57%
|
($87.2m)
-56.29%
|
($115.2m)
-32.18%
|
($247.6m)
-114.87%
|
($71.1m)
+71.28%
|
($111.7m)
-57.06%
|
|
| Cash flows from investing activities: | ||||||||||||
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | $54k | ($14k) | ($2k) | $0 | $0 | — | — | — | — | |
| Payments to Acquire Property, Plant, and Equipment | ($701k) | ($1.8m) | $1.7m | $1.4m | $493k | $2.6m | $3.4m | $2.4m | $3.9m | $2.4m | ($2.2m) | |
| Purchases of marketable securities | — | ($13.5m) | ($133.3m) | ($88.0m) | ($242.3m) | ($315.0m) | ($255.8m) | ($596.0m) | ($1.2b) | ($607.9m) | — | |
| Maturities of marketable securities | — | $6.3m | $65.8m | $73.5m | $96.6m | $244.0m | $225.8m | $439.9m | $692.6m | $680.2m | — | |
| Sales of marketable securities | — | — | $6.0m | $18.1m | $0 | $4.0m | $0 | $0 | — | — | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | — | $439.9m | $692.6m | $680.2m | — | |
| Net Cash Provided by (Used in) Investing Activities | ($3.6m) | ($8.9m) | ($63.2m) | $2.3m | ($146.2m) | ($69.7m) | ($33.4m) | ($158.5m) | ($502.6m) | $70.0m | ($92.7m) | |
| Cash flows from financing activities: | ||||||||||||
| Issuance Of Capital Stock | — | — | — | — | — | — | $95.0m | $309.8m | $654.2m | $24.9m | $216.3m | |
| Proceeds from Issuance of Common Stock | — | — | — | $50.3m | $100.7m | $86.0m | $86.1m | $281.2m | $274.4m | $0 | $216.3m | |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | — | — | — | $0 | $6.6m | $57.3m | $8.9m | $28.6m | $379.9m | $24.9m | $216.3m | |
| Proceeds from exercise of common stock options | — | $226k | $91k | $289k | $1.2m | $1.5m | $1.4m | $9.6m | $12.5m | $3.4m | — | |
| Common Stock Issuance | — | — | — | — | — | — | $95.0m | $309.8m | $654.2m | $24.9m | $216.3m | |
| Net Cash Provided by (Used in) Financing Activities | $5.8m |
$17.5m
+200.73%
|
$105.4m
+502.50%
|
$50.6m
-51.97%
|
$128.8m
+154.40%
|
$145.5m
+12.97%
|
$97.2m
-33.20%
|
$362.7m
+273.30%
|
$677.6m
+86.80%
|
$29.8m
-95.60%
|
$362.8m
+1118.38%
|
|
| Net increase (decrease) in cash, cash equivalents and restricted cash | — | ($3.7m) | $14.6m | $13.6m | $38.0m | $20.0m | ($23.4m) | $89.0m | ($72.6m) | $28.7m | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | $14.6m | $13.6m | $38.0m | $20.0m | ($23.4m) | $89.0m | ($72.6m) | $28.7m | $273.9m | |
| Beginning Cash Position | — | — | — | — | — | — | $92.2m | $68.7m | $157.8m | $85.2m | $115.5m | |
| Cash, cash equivalents and restricted cash, at beginning of period | — | $6.0m | $20.6m | $34.2m | $72.1m | $92.2m | $68.7m | $157.8m | $85.2m | $113.8m | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $20.6m | $34.2m | $72.1m | $92.2m | $68.7m | $157.8m | $85.2m | $113.8m | $273.9m | |
| Restricted cash | — | $71k | $106k | $106k | $106k | $106k | $106k | $757k | $805k | $1.0m | — | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Income Tax Expense (Benefit) | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Operating Lease, Expense | — | — | — | $1.5m | $1.5m | $1.7m | $1.7m | — | — | — | — | |
| Right-of-use asset obtained in exchange for a new operating lease liability | — | — | — | $0 | $1.2m | $0 | $0 | $1.3m | $18.0m | $6.2m | — | |
| Additional Financial Items | ||||||||||||
| Proceeds from Stock Options Exercised | — | — | $91k | $289k | $1.2m | $1.5m | $1.4m | $9.6m | $12.5m | $3.4m | — | |
| General and Administrative Expense | — | — | $4.7m | $10.0m | $15.2m | $20.1m | $23.9m | $28.3m | $39.3m | $63.3m | — | |
| Investment Income, Interest | — | — | $2.0m | $2.3m | — | — | — | — | — | — | — | |
| Operating Expenses | — | — | $36.4m | $44.3m | $54.9m | $78.2m | $113.4m | $157.8m | $334.0m | $378.0m | — | |
| Payments of Financing Costs | — | — | $71k | — | — | — | — | — | — | — | — | |
| Contract assets and liabilities | — | — | — | — | — | — | — | ($13.8m) | $0 | ($6.0m) | — | |
| Contract liabilities | — | — | — | $0 | $83.8m | ($23.5m) | ($46.5m) | ($13.8m) | $0 | — | — | |
| Lease liabilities | — | — | — | ($1.2m) | ($49k) | ($1.5m) | ($1.7m) | ($1.9m) | ($1.4m) | $2.6m | — | |
| Proceeds from issuances of pre-funded warrants | — | — | — | — | — | $0 | $0 | $42.2m | $9.4m | $0 | — | |
| Proceeds from ESPP purchases | — | — | — | $0 | $326k | $697k | $755k | $1.2m | $1.4m | $1.5m | — | |
| Vesting of early exercised options and restricted stock | — | $120k | $189k | $114k | $56k | $24k | $0 | $0 | — | — | — | |
| Unpaid offering costs | — | — | — | — | $0 | $0 | $39k | $43k | $0 | $0 | — | |
| Unpaid at-the-market offering program costs | — | — | — | — | — | — | $0 | $0 | $13k | — | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | — | $97.2m | $362.7m | $677.6m | $29.8m | $362.8m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | — | ($33.4m) | ($158.5m) | ($502.6m) | $70.0m | ($92.7m) | |
| Change In Account Payable | — | — | — | — | — | — | $1.9m | $2.6m | $8.3m | $2.7m | $12.3m | |
| Change In Other Working Capital | — | — | — | — | — | ($23.5m) | ($46.5m) | ($13.8m) | — | ($6.0m) | ($6.0m) | |
| Change In Payable | — | — | — | — | — | — | $1.9m | $2.6m | $8.3m | $2.7m | $12.3m | |
| Change In Prepaid Assets | — | — | — | — | — | — | ($2.1m) | ($2.0m) | ($6.2m) | ($7.8m) | ($3.4m) | |
| Changes In Cash | — | — | — | — | — | — | ($23.4m) | $89.0m | ($72.6m) | $28.7m | $158.4m | |
| End Cash Position | — | — | — | — | — | — | $68.7m | $157.8m | $85.2m | $113.8m | $273.9m | |
| Financing Cash Flow | — | — | — | — | — | — | $97.2m |
$362.7m
+273.30%
|
$677.6m
+86.80%
|
$29.8m
-95.60%
|
$362.8m
+1118.38%
|
|
| Free Cash Flow | — | — | — | — | — | — | ($90.6m) | ($117.6m) | ($251.4m) | ($73.5m) | ($113.9m) | |
| Gain Loss On Sale Of PPE | — | — | — | — | — | $0 | $0 | — | — | — | $0 | |
| Investing Cash Flow | — | — | — | — | — | — | ($33.4m) | ($158.5m) | ($502.6m) | $70.0m | ($92.7m) | |
| Net PPE Purchase And Sale | — | — | — | — | — | — | ($3.4m) | ($2.4m) | ($3.9m) | ($2.4m) | ($2.2m) | |
| Net Preferred Stock Issuance | — | — | — | — | — | $0 | $0 | $42.2m | $9.4m | — | $9.4m | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | — | $2.2m | $53.0m | $23.3m | $4.9m | $146.5m | |
| Purchase Of PPE | — | — | — | — | — | — | ($3.4m) | ($2.4m) | ($3.9m) | ($2.4m) | ($2.2m) | |
| Net Investment Purchase And Sale | — | — | — | — | — | — | ($30.0m) | ($156.1m) | ($498.7m) | $72.3m | ($90.5m) | |
| Purchase Of Investment | — | — | — | — | — | — | ($255.8m) | ($596.0m) | ($1.2b) | ($607.9m) | ($731.2m) | |
| Sale Of Investment | — | — | — | — | — | — | $225.8m | $439.9m | $692.6m | $680.2m | $640.6m | |
| Cash and cash equivalents | $2.2m | $6.0m | $20.5m | $34.1m | $72.0m | $92.0m | $68.6m | $157.0m | $84.4m | $112.8m | $115.5m | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Change In Cash Supplemental As Reported | — | — | — | — | — | — | ($23.4m) | $89.0m | ($72.6m) | $28.7m | — | |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | $19k | $99k | $91k | $82k | $71k | $60k | $69k | $25k | $0 | — | |
| Income Taxes Paid, Net | $250k | — | $1k | $1k | $1k | $4k | $0 | $0 | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.